Sotabase

Career

· Machine Learning Intern, Generate:Biomedicines2025–2025
· Doctor of Philosophy - PhD, Computer Science, University of California, Berkeley2021–2026
· Graduate Student Researcher, University of California, Berkeley2021–
· Independent Project, The Johns Hopkins University (Battle Lab, mentored by Prof. Alexis Battle)2020–2021
· Data Science Intern, Bayesian Health2019–2019
· Research Assistant, The Johns Hopkins University (Neurodata Lab, advised by Prof. Joshua Vogelstein)2018–2019
· Bachelor of Science - BS, Applied Mathematics & Statistics; Computer Science, 3.96/4.00, The Johns Hopkins University2016–2019

Publications (192)

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Journal of Clinical Oncology · 2016
854
cited
Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
Journal of Clinical Oncology · 2013
469
cited
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.
The Lancet Oncology · 2020
468
cited
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
The Lancet · 2016
464
cited
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Clinical Cancer Research · 2020
435
cited
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
The Lancet Oncology · 2018
411
cited
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
Journal of Clinical Oncology · 2022
191
cited
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
Journal of Clinical Oncology · 2018
183
cited
Purine metabolism regulates DNA repair and therapy resistance in glioblastoma
Nature Communications · 2020
181
cited
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial
Journal of Hematology & Oncology · 2020
118
cited
Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro.
Biochemical and Biophysical Research Communications - BBRC · 2014
110
cited
A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma
Anti-Cancer Drugs · 2012
96
cited
miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1.
Biochemical and Biophysical Research Communications - BBRC · 2015
95
cited
Ruscogenin induces ferroptosis in pancreatic cancer cells
Oncology Report · 2019
86
cited
MiR-1271 Inhibits Cell Proliferation, Invasion and EMT in Gastric Cancer by Targeting FOXQ1
Cellular Physiology and Biochemistry · 2015
83
cited
Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
Molecular Cancer · 2023
83
cited
Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
Journal of Hematology & Oncology · 2017
79
cited
A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.
2012
78
cited
TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185.
International Journal of Clinical and Experimental Pathology · 2015
78
cited
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study
Journal of Clinical Oncology · 2021
77
cited
Sotabase
Junhao (Bear) Xiong | Researcher Profile | Sotabase | Sotabase